Metoclopramide

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Metoclopramide

Examples of brand names: Paspertin [DE]

ATC code: A03FA01

Main use (for orientation): Nausea; vomiting

Documented research summary

A case report describes dystonia after low-dose metoclopramide five days after last cannabis use; cannabis-related enzyme inhibition remains the authors' hypothesis without exposure measurement. In rats, CBDA enhanced the anti-nausea effect of a previously ineffective metoclopramide dose. Historical THC-versus-metoclopramide comparisons assess alternatives, not a simultaneous interaction.

Uncertainties and limitations

Case with previous haloperidol-associated dystonia; discontinuation/withdrawal and individual susceptibility are confounders. Do not extrapolate the CBDA rat finding to human doses or CBD. Missing data do not establish safety.

Separately recorded findings

2 separately recorded findings. Each statement applies to its documented study context.

CBDA – laboratory and animal studies

Finding ID: B0437

Type of result: Pharmacodynamics; combination effect in an animal model

Observation: CBDA enhanced suppression of lithium-induced conditioned gaping at a metoclopramide amount ineffective alone.

Mechanism: Antiemetic/anti-nausea pharmacodynamics; no pharmacokinetic measurement

Study type: Controlled rat experiment

Context studied: Rats; metoclopramide 0.3 mg/kg plus CBDA 0.1 µg/kg. These are experimental animal amounts, not instructions for use.

Clinical interpretation: Scientific model finding; no clinical combination recommendation.

Limitations and uncertainties: Original abstract assessed. Behavioural test, not human efficacy or safety evidence; do not extrapolate to CBD.

Original sources for this finding: Suppression of lithium chloride-induced conditioned gaping (a model of nausea-induced behaviour) in rats (using the taste reactivity test) with metoclopramide is enhanced by cannabidiolic acid. [VE_MED_24012649]

Cannabis; composition not quantified – clinical signals

Finding ID: B0438

Type of result: Adverse event; pair causality not established

Observation: Dystonia after low-dose metoclopramide reported following recently discontinued heavy cannabis use.

Mechanism: Authors' hypothesis of altered drug disposition after cannabis use; no concentration measurement

Study type: Single case report with substantial confounders

Context studied: Young female patient; last cannabis use five days earlier; previous dystonia with haloperidol.

Clinical interpretation: Safety context for professional individual assessment, not a quantified pair risk.

Limitations and uncertainties: Previous reaction, individual susceptibility and withdrawal complicate attribution; no specific CBD/THC interaction or causal enzyme inhibition demonstrated. Abstract access.

Original sources for this finding: Low-dose metoclopramide-induced dystonia in cannabis withdrawal syndrome manifesting as intractable nausea and vomiting. [VE_MED_40379294]

References and access status

[VE_LABEL_D0274] METOCLOPRAMIDE (METOCLOPRAMIDE HYDROCHLORIDE) INJECTION [HENRY SCHEIN, INC.]

Original source / bibliographic reference

Authors: Respective marketing authorisation holder; regulatory product information

Year: 2026

Source type: Product information / SmPC / US Prescribing Information

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[VE_MED_40379294] Low-dose metoclopramide-induced dystonia in cannabis withdrawal syndrome manifesting as intractable nausea and vomiting.

Original source / bibliographic reference

Authors: Khamis A, Dygulski S.

Year: 2025

Source type: Journal Article; Case Reports

DOI: 10.1136/bcr-2025-264815

PMID: 40379294

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

[VE_MED_24012649] Suppression of lithium chloride-induced conditioned gaping (a model of nausea-induced behaviour) in rats (using the taste reactivity test) with metoclopramide is enhanced by cannabidiolic acid.

Original source / bibliographic reference

Authors: Rock EM, Parker LA.

Year: 2013

Source type: Research Support, Non-U.S. Gov't; Journal Article

DOI: 10.1016/j.pbb.2013.08.012

PMID: 24012649

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility